Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.
Keytruda (pembrolizumab) was effective in treating triple-negative breast cancer regardless of whether women had received previous treatment, according to data presented at the 2017 American Society of Clinical Oncology (ASCO) ... Read more
The number of women living with metastatic breast cancer (MBC) is increasing. But that’s not necessarily a bad thing, say researchers, noting that today’s better treatments allow patients to ... Read more
AbbVie’s investigational oral PARP inhibitor veliparib was not effective against early-stage triple-negative breast cancer when given in combination with chemotherapy, the company recently announced. Despite the drawback, AbbVie researchers ... Read more
Three national databases report highly varying rates of immediate breast reconstruction (IBR) among minority breast cancer patients undergoing breast removal for breast cancer, bringing focus to the already important issue of ... Read more
The breast cancer therapy Ibrance (palbociclib) offers no more benefits than treatments with which it was compared in clinical trials, according to an analysis by the German Institute for Quality and ... Read more
Researchers have identified two new factors that may help to determine whether a patient with estrogen receptor-positive breast cancer will respond to treatment. In addition to preventing the estrogen receptor ... Read more
Adding the experimental PARP inhibitor veliparib to chemotherapy increased the number of patients who responded to treatment without worsening side effects, but failed to lengthen progression-free survival times, a ... Read more